-
公开(公告)号：WO2002078698A2
公开(公告)日：2002-10-10
申请号：PCT/FR2002/001052
申请日：2002-03-27
Applicant: PIERRE FABRE MEDICAMENT , CARON, Gerssende , JEANNIN, Pascale , BONNEFOY, Jean-Yves
Inventor： CARON, Gerssende , JEANNIN, Pascale , BONNEFOY, Jean-Yves
IPC: A61K31/415
CPC classification number: A61K31/00 , A61K31/417 , A61K39/39 , A61K39/395 , A61K2039/55511 , A61K2300/00
Abstract: La présente invention se rapporte à l'utilisation de l'histamine pour induire la polarisation des cellules dendritiques, et plus particulièrement pour induire la polarisation des cellules dendritiques en cellules dendritiques de type 2, utiles notamment pour le traitement thérapeutique et prophylactique des pathologies associées à une réponse Th1 excessive.
Abstract translation: 本发明涉及组胺诱导树突状细胞极化的用途，更具体地说，是诱导树突状细胞向2型树突状细胞的极化，特别是用于治疗和预防治疗与 过多的Th1反应。
-
公开(公告)号：WO2008067995A8
公开(公告)日：2008-08-21
申请号：PCT/EP2007010527
申请日：2007-12-04
Applicant: TRANSGENE SA , ACRES BRUCE , BONNEFOY JEAN-YVES
Inventor： ACRES BRUCE , BONNEFOY JEAN-YVES
IPC: A61K39/00 , A61K31/00 , A61K31/4745 , C12N15/863
CPC classification number: A61K39/0011 , A61K2039/545 , A61K2039/55
Abstract: The present invention concerns methods for raising an immune response to a targeted antigen in a patient for treating human disease by administering an immunogenic composition wherein said patient is selected in a patient population of interest.
Abstract translation: 本发明涉及用于通过施用免疫原性组合物来提高对患者中靶向抗原的免疫应答以治疗人类疾病的方法，其中所述患者在感兴趣的患者群体中选择。
-
公开(公告)号：WO2008067995A3
公开(公告)日：2008-06-12
申请号：PCT/EP2007/010527
申请日：2007-12-04
Applicant: TRANSGENE S.A. , ACRES, Bruce , BONNEFOY, Jean-Yves
Inventor： ACRES, Bruce , BONNEFOY, Jean-Yves
IPC: A61K39/00 , C12N15/863 , A61K31/4745 , A61K31/00
Abstract: The present invention concerns methods for raising an immune response to a targeted antigen in a patient for treating human disease by administering an immunogenic composition wherein said patient is selected in a patient population of interest.
-
公开(公告)号：WO2008067995A2
公开(公告)日：2008-06-12
申请号：PCT/EP2007010527
申请日：2007-12-04
Applicant: TRANSGENE SA , ACRES BRUCE , BONNEFOY JEAN-YVES
Inventor： BONNEFOY JEAN-YVES
IPC: A61K39/00 , A61K31/00 , A61K31/4745 , C12N15/863
CPC classification number: A61K39/0011 , A61K2039/545 , A61K2039/55
Abstract: The present invention concerns methods for raising an immune response to a targeted antigen in a patient for treating human disease by administering an immunogenic composition wherein said patient is selected in a patient population of interest.
Abstract translation: 本发明涉及通过施用免疫原性组合物来增加患者中靶向抗原的免疫应答以治疗人类疾病的方法，其中在感兴趣的患者群中选择所述患者。
-
5.发明申请POLARISATION OF DENDRITIC CELLS (TREATMENT OF INFECTIONS, CANCER AND AUTOIMMUNE DISEASES) USING HISTAMINE 审中-公开使用组胺来感染细胞（感染，癌症和自身免疫性疾病的治疗）的极化
公开(公告)号：WO02078698A3
公开(公告)日：2003-05-30
申请号：PCT/FR0201052
申请日：2002-03-27
Applicant: PF MEDICAMENT , CARON GERSSENDE , JEANNIN PASCALE , BONNEFOY JEAN-YVES
Inventor： CARON GERSSENDE , JEANNIN PASCALE , BONNEFOY JEAN-YVES
IPC: A61K31/00 , A61K31/417 , A61K39/39 , A61K39/395 , A61P31/00 , A61P31/12 , A61P33/00 , A61P35/00 , A61P37/00
CPC classification number: A61K31/00 , A61K31/417 , A61K39/39 , A61K39/395 , A61K2039/55511 , A61K2300/00
Abstract: The invention relates to the use of histamine to induce the polarisation of dendritic cells and, more specifically, to induce the polarisation of dendritic cells into type 2 dendritic cells, which are used, in particular, for the therapeutic and prophylactic treatment of pathologies associated with an excessive Th1 response.
Abstract translation: 本发明涉及组胺诱导树突状细胞极化的用途，更具体地说，是诱导树突状细胞向2型树突状细胞的极化，特别是用于治疗和预防治疗与 过多的Th1反应。
-
Patent Agency Ranking6.发明申请MONOCLONAL ANTIBODIES TO HUMAN LYMPHOCYTE IgE RECEPTORS, HYBRIDOMAS PRODUCING SUCH ANTIBODIES, AND KITS FOR USING SUCH ANTIBODIES 审中-公开人淋巴细胞IgE受体单克隆抗体，生产此类抗体的混合物和使用此类抗体的试剂盒
公开(公告)号：WO1987007302A2
公开(公告)日：1987-12-03
申请号：PCT/EP1987000264
申请日：1987-05-20
Applicant: LABORATOIRES UNICET , BONNEFOY, Jean, Yves , WIJDENES, John , PERONNE, Catherine , AUBRY-LACHAINAYE, Jean-Pierre , BANCHEREAU, Jacques
Inventor： LABORATOIRES UNICET
IPC: C12P21/00
CPC classification number: C07K16/2851
Abstract: Monoclonal antibodies inhibiting binding of soluble IgE to human lymphocytes, to monoclonal antibodies to human lymphocyte IgE receptors, and to hybridomas producing such antibodies. These antibodies are preferably of the immunoglobulin subclass IgG1. They can be used in assaying soluble Fc epsilon RII and cells carrying these Fc epsilon RII receptors. The invention further provides kits for assaying soluble Fc epsilon RII and also cells carrying these Fc epsilon RII receptors by means of monoclonal antibodies described herein.
Abstract translation: 抑制可溶性IgE与人类淋巴细胞结合的单克隆抗体，对人淋巴细胞IgE受体的单克隆抗体，以及产生此类抗体的杂交瘤。 这些抗体优选为免疫球蛋白亚类IgG1。 它们可用于测定可溶性FcεRII和携带这些FcεRII受体的细胞。 本发明还提供了用于通过本文所述的单克隆抗体测定可溶性FcεRII以及携带这些FcεRII受体的细胞的试剂盒。
-
公开(公告)号：WO2007147529A3
公开(公告)日：2008-02-28
申请号：PCT/EP2007005303
申请日：2007-06-15
Applicant: TRANSGENE SA , BONNEFOY JEAN-YVES , PAUL STEPHANE
Inventor： BONNEFOY JEAN-YVES , PAUL STEPHANE
IPC: A61K39/39 , A61K39/285
CPC classification number: A61K39/39 , A61K39/0011 , A61K39/12 , A61K2039/5256 , A61K2039/54 , A61K2039/55511 , A61K2039/55533 , A61K2039/585 , C07K14/005 , C12N7/00 , C12N2710/14143 , C12N2710/20022 , C12N2710/20034
Abstract: The present invention concerns new recombinant viral vaccines. In particular the present invention provides combination products that comprise recombinant viral vectors and specific compounds able to improve the immune response raised in vivo by said recombinant viral vectors.
Abstract translation: 本发明涉及新的重组病毒疫苗。 特别地，本发明提供了包含重组病毒载体和能够改善由所述重组病毒载体在体内产生的免疫应答的特异性化合物的组合产物。
-
8.发明申请METHOD FOR PREPARING A POLYPEPTIDE SOLUBLE IN AN AQUEOUS SOLVENT IN THE ABSENCE OF DETERGENT 审中-公开在洗涤剂无效的情况下在水溶液中制备多肽溶液的方法
公开(公告)号：WO0149705A3
公开(公告)日：2002-02-14
申请号：PCT/FR0100023
申请日：2001-01-04
Applicant: PF MEDICAMENT , BAUSSANT THIERRY , JEANNIN PASCALE , DELNESTE YVES , LAWNY FRANCOIS , BONNEFOY JEAN YVES
Inventor： BAUSSANT THIERRY , JEANNIN PASCALE , DELNESTE YVES , LAWNY FRANCOIS , BONNEFOY JEAN-YVES
IPC: A61K47/42 , A61K38/00 , A61K39/00 , A61K39/39 , A61P31/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P37/02 , C07K1/16 , C07K1/34 , C07K14/26 , C07K14/205
CPC classification number: C07K14/26 , C07K1/34 , Y10T436/25 , Y10T436/25125 , Y10T436/25375
Abstract: The invention concerns a novel method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent, and polypeptides obtainable by said method. The invention also concerns the use of said polypeptides, in particular for preparing medicines or vaccines, for fighting against bacterial and viral infections or cancers.
Abstract translation: 本发明涉及在不存在洗涤剂的情况下制备可溶于水性溶剂的多肽的新方法，以及可通过所述方法获得的多肽。 本发明还涉及所述多肽的用途，特别是用于制备药物或疫苗以抵抗细菌和病毒感染或癌症。
-
9.发明申请CLONING, EXPRESSION AND CHARACTERISATION OF A GENE EXPRESSED IN TUMOUR CELLS AND INVOLVED IN THE REGULATION OF THE IMMUNE RESPONSE 审中-公开肿瘤细胞表达的基因的克隆，表达和表征及参与免疫应答的调控
公开(公告)号：WO0131003B1
公开(公告)日：2001-10-11
申请号：PCT/FR0003032
申请日：2000-10-30
Applicant: PF MEDICAMENT , DELNESTE YVES , MAGISTRELLI GIOVANNI , JEANNIN PASCALE , BONNEFOY JEAN YVES
Inventor： DELNESTE YVES , MAGISTRELLI GIOVANNI , JEANNIN PASCALE , BONNEFOY JEAN-YVES
IPC: G01N33/50 , A61K31/7088 , A61K35/76 , A61K38/00 , A61K39/395 , A61K48/00 , A61P31/00 , A61P31/04 , A61P31/10 , A61P31/12 , A61P33/00 , A61P35/00 , A61P37/00 , A61P37/02 , C07K14/47 , C07K14/705 , C07K16/30 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12P21/02 , C12Q1/68 , G01N33/15 , G01N33/53 , A01K67/027 , A61K38/17 , C12N15/11 , G01N33/68
CPC classification number: C07K14/705 , A01K2217/05 , A61K38/00
Abstract: The invention concerns the identification and the characterisation of a novel gene expressed in tumour cells and involved in the regulation of the immune response, the cloning and the characterisation of its cDNA and the corresponding polypeptides. The invention also concerns vectors containing a nucleic acid coding for said gene, cells transformed by said vectors and diagnostic methods and selection methods of a chemical or biological compound capable of directly or indirectly interacting with a nucleic acid or a polypeptide of the invention. The invention further concerns compounds for treating immune pathologies, in particular autoimmune diseases and cancer.
Abstract translation: 本发明涉及肿瘤细胞中表达的新基因的鉴定和表征，其涉及调节免疫应答，克隆和表达其cDNA和相应的多肽。 本发明还涉及含有编码所述基因的核酸，由所述载体转化的细胞的载体以及能够与本发明的核酸或多肽直接或间接相互作用的化学或生物化合物的诊断方法和选择方法。 本发明还涉及用于治疗免疫病状，特别是自身免疫性疾病和癌症的化合物。
-
10.发明申请BINDING AGENTS FOR TREATMENT OF INFLAMMATORY, AUTOIMMUNE OR ALLERGIC DISEASES 审中-公开治疗炎症，自身免疫或过敏性疾病的结合剂
公开(公告)号：WO1996012742A1
公开(公告)日：1996-05-02
申请号：PCT/EP1995004110
申请日：1995-10-20
Inventor： GLAXO GROUP LIMITED
IPC: C07K16/28
CPC classification number: C12N9/6432 , A61K38/00 , A61K2039/505 , C07K14/005 , C07K14/7056 , C07K16/2845 , C07K16/2851 , C12N2710/16222 , C12N2710/16622 , C12Y304/21006
Abstract: Binding agents to CD11b, CD11c, CD21, CD23, a 70 to 85 KDa protein expressed on endothelial cells or a 115 KDa protein expressed on endothelial cells, can be useful in the treatment of inflammatory, autoimmune or allergic disease.
Abstract translation: CD11b，CD11c，CD21，CD23，内皮细胞上表达的70至85 KDa蛋白或内皮细胞上表达的115 KDa蛋白的结合剂可用于治疗炎症，自身免疫或过敏性疾病。
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.009 seconds)
